SkinPen Wins the Barry Knapp Award for Product Innovation of the Year in the UK, Nominated by BioActiveAesthetics, UK Distributor and Supplier for Bellus Medical

JOHNSON CITY, Tennessee and DALLAS, Dec. 18, 2018 /PRNewswire/ -- Bellus Medical is again proving its SkinPen is setting a new standard as the premier FDA-cleared microneedling device. Bellus Medical would like to thank Kathy Taylor-Brewin, Managing Director of BioActiveAesthetics, the UK distributor and supplier for Bellus Medical, for nominating SkinPen for this prestigious award.

Each year this award is presented at the renowned Aesthetics Awards to products launched in the UK that represent genuine innovation or product advancement leading to treatment for new indications, quicker or easier treatments, better treatment outcomes, enhanced patient safety, backed up by sound evidence. The product scored extremely well with the judges, with one commenting, "An important innovation within the generic microneedling sector… I believe this product represents a benchmark for safety and quality in microneedling."

"Bellus Medical, in partnership with BioActiveAesthetics, is honored to have received this prestigious award. SkinPen is a first in class technology that delivers safe and effective results," said Joe Proctor, President of Bellus Medical. "We are thankful to Medical Aesthetics Group for recognizing our innovation in aesthetics. I was especially proud to have received the award with Jenn Block and Thomas Hitchcock, Ph.D. who worked together to finalize the development process. I would like to share a special thank you for Ashley Dynan who worked so hard to get the CE Mark in the UK. It's a great win for the Crown family, and we are looking forward to continuing to innovate and improve technology in the field of Dermatology and Aesthetics."

"I am so proud to be part of the success of SkinPen. The award is truly deserved for Bellus Medical's product innovation which sets a new standard for patient safety using mechanical microneedling devices," said Kathy Taylor-Brewin.

"After all the time, resources and effort that went into the development of Precision, it has been very satisfying to see how well the device has been accepted by the medical community. Additionally, to see it winning awards both in the United States and now internationally has been quite validating," said Crown's Chief Science Officer, Thomas Hitchcock, Ph.D. "We took a risk in redesigning the microneedling device from the ground up, and we are pleased to see that the innovation and thoughtful engineering that went into Precision is what our customers wanted in a next-generation microneedling device."